Literature DB >> 19221814

The spectrum of somatic and germline NF1 mutations in NF1 patients with spinal neurofibromas.

Meena Upadhyaya1, Gill Spurlock, Lan Kluwe, Nadia Chuzhanova, Emma Bennett, Nick Thomas, Abhijit Guha, Victor Mautner.   

Abstract

Neurofibromatosis type 1 (NF1) is a common inherited complex multi-system disorder associated with the growth of various benign and malignant tumors. About 40% of NF1 patients develop spinal tumors, of whom some have familial spinal neurofibromatosis (FSNF), a variant form of NF1 in which patients present with multiple bilateral spinal tumors but have few other clinical features of the disease. We have studied 22 spinal neurofibromas derived from 14 unrelated NF1 patients. Seven of these patients satisfied the diagnostic criteria of NF1 while the remaining seven had only few features of NF1. The latter group defined as FSNF harbored significantly higher number of missense or missense and splice-site germline mutations compared to the group with classical NF1. This is the first study to describe NF1 somatic mutations in spinal neurofibromas. Loss-of-heterozygosity (LOH) was identified in 8/22 of the spinal tumors, 75% of LOH observed was found to result from mitotic recombination, suggesting that this may represent a frequent mutational mechanisms in these benign tumors. No evidence for LOH of the TP53 gene was found in these tumors.

Entities:  

Mesh:

Year:  2009        PMID: 19221814     DOI: 10.1007/s10048-009-0178-0

Source DB:  PubMed          Journal:  Neurogenetics        ISSN: 1364-6745            Impact factor:   2.660


  38 in total

1.  NF1 mutations and clinical spectrum in patients with spinal neurofibromas.

Authors:  L Kluwe; M Tatagiba; C Fünsterer; V-F Mautner
Journal:  J Med Genet       Date:  2003-05       Impact factor: 6.318

2.  Independent NF1 mutations in two large families with spinal neurofibromatosis.

Authors:  L Messiaen; V Riccardi; J Peltonen; O Maertens; T Callens; S L Karvonen; E-L Leisti; J Koivunen; I Vandenbroucke; K Stephens; M Pöyhönen
Journal:  J Med Genet       Date:  2003-02       Impact factor: 6.318

3.  Mitotic recombination effects homozygosity for NF1 germline mutations in neurofibromas.

Authors:  E Serra; T Rosenbaum; M Nadal; U Winner; E Ars; X Estivill; C Lázaro
Journal:  Nat Genet       Date:  2001-07       Impact factor: 38.330

4.  Rb and TP53 pathway alterations in sporadic and NF1-related malignant peripheral nerve sheath tumors.

Authors:  S Birindelli; F Perrone; M Oggionni; C Lavarino; B Pasini; B Vergani; G N Ranzani; M A Pierotti; S Pilotti
Journal:  Lab Invest       Date:  2001-06       Impact factor: 5.662

5.  Somatic NF1 mutational spectrum in benign neurofibromas: mRNA splice defects are common among point mutations.

Authors:  E Serra; E Ars; A Ravella; A Sánchez; S Puig; T Rosenbaum; X Estivill; C Lázaro
Journal:  Hum Genet       Date:  2001-05       Impact factor: 4.132

6.  Somatic loss of wild type NF1 allele in neurofibromas: Comparison of NF1 microdeletion and non-microdeletion patients.

Authors:  Thomas De Raedt; Ophélia Maertens; Magdalena Chmara; Hilde Brems; Ine Heyns; Raf Sciot; Elisa Majounie; Meena Upadhyaya; Sofie De Schepper; Frank Speleman; Ludwine Messiaen; Joris Robert Vermeesch; Eric Legius
Journal:  Genes Chromosomes Cancer       Date:  2006-10       Impact factor: 5.006

7.  Toward a survey of somatic mutation of the NF1 gene in benign neurofibromas of patients with neurofibromatosis type 1.

Authors:  I Eisenbarth; K Beyer; W Krone; G Assum
Journal:  Am J Hum Genet       Date:  2000-02       Impact factor: 11.025

8.  Germline and somatic NF1 gene mutation spectrum in NF1-associated malignant peripheral nerve sheath tumors (MPNSTs).

Authors:  M Upadhyaya; Lan Kluwe; G Spurlock; Bisma Monem; E Majounie; K Mantripragada; Martino Ruggieri; N Chuzhanova; D G Evans; R Ferner; N Thomas; A Guha; V Mautner
Journal:  Hum Mutat       Date:  2008-01       Impact factor: 4.878

9.  Functional splicing assay shows a pathogenic intronic mutation in neurofibromatosis type 1 (NF1) due to intronic sequence exonization.

Authors:  M Raponi; M Upadhyaya; D Baralle
Journal:  Hum Mutat       Date:  2006-03       Impact factor: 4.878

10.  Characterization of the somatic mutational spectrum of the neurofibromatosis type 1 (NF1) gene in neurofibromatosis patients with benign and malignant tumors.

Authors:  Meena Upadhyaya; Song Han; Claudia Consoli; Elisa Majounie; Martin Horan; Nick S Thomas; Christopher Potts; Sian Griffiths; Martino Ruggieri; Andreas von Deimling; David N Cooper
Journal:  Hum Mutat       Date:  2004-02       Impact factor: 4.878

View more
  16 in total

1.  Back to the future: proceedings from the 2010 NF Conference.

Authors:  Susan M Huson; Maria T Acosta; Allan J Belzberg; Andre Bernards; Jonathan Chernoff; Karen Cichowski; D Gareth Evans; Rosalie E Ferner; Marco Giovannini; Bruce R Korf; Robert Listernick; Kathryn N North; Roger J Packer; Luis F Parada; Juha Peltonen; Vijaya Ramesh; Karlyne M Reilly; John W Risner; Elizabeth K Schorry; Meena Upadhyaya; David H Viskochil; Yuan Zhu; Kim Hunter-Schaedle; Filippo G Giancotti
Journal:  Am J Med Genet A       Date:  2010-12-22       Impact factor: 2.802

2.  Familial spinal neurofibromatosis due to a multiexonic NF1 gene deletion.

Authors:  Antonio Pizzuti; Irene Bottillo; Francesca Inzana; Valentina Lanari; Francesca Buttarelli; Isabella Torrente; Anna Teresa Giallonardo; Alessandro De Luca; Bruno Dallapiccola
Journal:  Neurogenetics       Date:  2011-03-02       Impact factor: 2.660

3.  Spinal neurofibromatosis associated with classical neurofibromatosis type 1: genetic characterisation of an atypical case.

Authors:  Kursat bora Carman; Ayten Yakut; Banu Anlar; Sukriye Ayter
Journal:  BMJ Case Rep       Date:  2013-02-14

Review 4.  Neurofibromatosis type 1-associated tumours: their somatic mutational spectrum and pathogenesis.

Authors:  Sebastian Laycock-van Spyk; Nick Thomas; David N Cooper; Meena Upadhyaya
Journal:  Hum Genomics       Date:  2011-10       Impact factor: 4.639

5.  Bilateral Mirror Image Cervical Neurofibroma in an Adult with Neurofibromatosis Type 1.

Authors:  Sharad Pandey; Kulwant Singh; Vivek Sharma; Mohammed Tabish Khan; Amrita Ghosh; Deepa Santhosh
Journal:  Malays J Med Sci       Date:  2017-02-24

6.  Analysis of steroid hormone effects on xenografted human NF1 tumor schwann cells.

Authors:  Hua Li; Xuelian Zhang; Lauren Fishbein; Frederick Kweh; Martha Campbell-Thompson; George Q Perrin; David Muir; Margaret Wallace
Journal:  Cancer Biol Ther       Date:  2010-10-15       Impact factor: 4.742

7.  Mitotic recombination of chromosome arm 17q as a cause of loss of heterozygosity of NF1 in neurofibromatosis type 1-associated glomus tumors.

Authors:  Douglas R Stewart; Alexander Pemov; Peter Van Loo; Eline Beert; Hilde Brems; Raf Sciot; Kathleen Claes; Evgenia Pak; Amalia Dutra; Chyi-Chia Richard Lee; Eric Legius
Journal:  Genes Chromosomes Cancer       Date:  2012-01-17       Impact factor: 5.006

8.  Increased rate of missense/in-frame mutations in individuals with NF1-related pulmonary stenosis: a novel genotype-phenotype correlation.

Authors:  Shay Ben-Shachar; Shlomi Constantini; Hen Hallevi; Emma K Sach; Meena Upadhyaya; Gareth D Evans; Susan M Huson
Journal:  Eur J Hum Genet       Date:  2012-10-10       Impact factor: 4.246

9.  Dissecting loss of heterozygosity (LOH) in neurofibromatosis type 1-associated neurofibromas: Importance of copy neutral LOH.

Authors:  Carles Garcia-Linares; Juana Fernández-Rodríguez; Ernest Terribas; Jaume Mercadé; Eva Pros; Llúcia Benito; Yolanda Benavente; Gabriel Capellà; Anna Ravella; Ignacio Blanco; Hildegard Kehrer-Sawatzki; Conxi Lázaro; Eduard Serra
Journal:  Hum Mutat       Date:  2011-01       Impact factor: 4.878

10.  Can the diagnosis of NF1 be excluded clinically? A lack of pigmentary findings in families with spinal neurofibromatosis demonstrates a limitation of clinical diagnosis.

Authors:  Emma Mm Burkitt Wright; Emma Sach; Saba Sharif; Oliver Quarrell; Thomas Carroll; Richard W Whitehouse; Meena Upadhyaya; Susan M Huson; D Gareth R Evans
Journal:  J Med Genet       Date:  2013-06-28       Impact factor: 6.318

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.